616-P: Long-Term Statin Persistence Is Poor among High-Risk Patients with Baseline Diabetes: A Real-World Administrative Claims Analysis

Abstract

Background: Statin persistence has been poor for over 2 decades, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking, particularly in patients with diabetes. Methods: This retrospective administrative claims analysis (Optum Research Database) analyzed long-term data on statin persistence in patients with high CV risk by diabetes and triglycerides (TG). Patients aged ≥45 years with diabetes and/or atherosclerotic CV disease with an index date and statin prescription filled in 2010 were included. Patients with TG ≥150 mg/dL were propensity-matched to a comparator cohort with TG <150 mg/dL and high-density lipoprotein cholesterol >40 mg/dL. Cohorts were followed for ≥6 months to March 2016. Results: In the elevated-TG and comparator cohorts (each n=23,181), mean follow-up was 41.4 and 42.5 months, mean age was 62.2 and 62.6 years, and 49.7% and 49.5% were female, respectively. In patients with and without baseline elevated-TG and/or baseline diabetes, statin persistence was poor, with ≤21% remaining on a prescription fill for index statin at 5 years (Figure). Conclusions: Statin persistence remains poor, particularly in patients with high CV risk, elevated TG, and diabetes. Better public health programs and patient education initiatives on the benefits of statins and the danger of statin discontinuation are needed. Disclosure P.P. Toth: Consultant; Self; Amarin Corporation, Amgen Inc., AstraZeneca, Kowa Pharmaceutical Europe Co. Ltd., Novo Nordisk Inc. Speaker's Bureau; Self; Amarin Corporation, Amgen Inc., Merck & Co., Inc., Novo Nordisk Inc., Regeneron Pharmaceuticals, Sanofi US. S. Philip: Employee; Self; Amarin Corporation. Stock/Shareholder; Self; Amarin Corporation. M. Hull: None. C.B. Granowitz: Employee; Self; Amarin Pharma Inc. Stock/Shareholder; Self; Amarin Pharma Inc.